Over five years, relapsing-remitting multiple sclerosis patients in France taking Tysabri have adopted more at-home dosing, a review found.

The CAR T-cell therapy KYV-101 is safe, and showed preliminary signs of efficacy in patients with progressive forms of MS in ...

Frexalimab was well tolerated and maintained disease control over two years in adults with relapsing MS in an open-label ...

Balance issues with MS make it difficult for columnist Leigh Anne Nelson to navigate stairs and aisles at stadium events.

Tolebrutinib was found to delay disability progression in people with nonrelapsing secondary progressive MS in a Phase 3 ...

Treatment with CNM-Au8 led to clinical improvements in relapsing-remitting MS patients that linked to signs of nerve cell ...

Pain is challenging, but it doesn't have to define your life. Episode 2 of Get Tough on Multiple Sclerosis offers practical ...

Sanofi‘s oral BTK inhibitor tolebrutinib significantly delayed the onset of six-month confirmed disability progression compared with a placebo, by 31%, in people with nonrelapsing secondary ...

Getting used to living with MS is like trying to cook in a kitchen that's unfamiliar, columnist Ben Hofmeister writes.

The Phase 4 ENABLE study is set to be first in the U.S. to collect real-world safety and efficacy data of Briumvi for ...

No added benefit was found in increasing the dose of Genentech’s Ocrevus (ocrelizumab) — to two to three times the currently approved 600 mg dose — in slowing disability progression in ...